Your browser doesn't support javascript.
loading
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
Mrowietz, Ulrich; Bachelez, Hervé; Burden, A David; Rissler, Michael; Sieder, Christian; Orsenigo, Roberto; Chaouche-Teyara, Kamel.
Affiliation
  • Mrowietz U; Psoriasis-Center, Department of Dermatology, University Medical Center, Schleswig-Holstein, Campus Kiel, Germany. Electronic address: umrowietz@dermatology.uni-kiel.de.
  • Bachelez H; Service de Dermatologie, AP-HP Hôpital Saint-Louis, Sorbonne Paris Cité Université Paris Diderot, Paris, France; INSERM UMR1163, Institut Imagine, Paris, France.
  • Burden AD; Institute of Infection Inflammation and Immunity, University of Glasgow, Glasgow, United Kingdom.
  • Rissler M; Novartis Pharma AG, Basel, Switzerland.
  • Sieder C; Novartis Pharma AG, Basel, Switzerland.
  • Orsenigo R; Novartis Farma S.p.A, Origgio, Italy.
  • Chaouche-Teyara K; Novartis Pharma AG, Basel, Switzerland.
J Am Acad Dermatol ; 80(5): 1344-1352, 2019 May.
Article in En | MEDLINE | ID: mdl-30716404
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents / Antibodies, Monoclonal Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2019 Type: Article